New Haven, the USA-based healthcare industry pioneer for independent quality assurance in pharmaceutical drugs, Valisure, received substantial investments from leading healthcare venture capital firms. The round took place on February 28, 2024. AlleyCorp, a New York-based venture capital firm investing in transformative companies across dedicated verticals for Healthcare, Diversified Technology, Robotics, and Social Impact, led the financing for the company. However, the amount of the investment was not disclosed.

The company also introduced Chip Phillips as the new Chief Executive Officer. Phillips is an accomplished healthcare executive with a strong focus in the pharmacy service space. Meanwhile, David Light, co-founder of the company, assumed the role of President. He plans to focus on continuing to grow the company’s thought leadership and overall mission through its broad network of government, industry, and academic partners.

Purpose of the investment by Valisure

With the latest proceeds, Valisure seeks to accelerate its rapid growth and impact. 

The company has plans to further fuel its research and development efforts. It also intends to expand its team of experts. Meanwhile, the company intends to further strengthen its position as a market leader in the critically needed, independent pharmaceutical quality assurance space. 

What the company’s official has to add 

Chip Phillips, Valisure’s newly appointed CEO, said, “I am pleased to join Valisure as the Chief Executive Officer at a time in the industry when supply chain concerns, drug shortages, fiscal pressures, and quality issues appear to be at an all-time high. I look forward to collaborating with the talented team and enabling Valisure to expand its work with the industry to strategically address these issues.”

David Light, President of Valisure, further added, “As President, I am eager to expand Valisure’s existing leadership in the independent pharmaceutical quality assurance space that we’ve rapidly created in the United States since we founded the company in 2015. I’m also looking forward to nurturing existing partnerships and strengthening strong relationships with leaders throughout healthcare. These endeavours are aimed at further growing our impact on pharmaceutical quality and safety and overall improving public health.”

About the company 

With independent quality assurance, Valisure is a cutting-edge technology business leading the charge to close a significant gap in the healthcare supply chain. Our goal is to completely transform the broken supply chain by bringing something vitally lacking to it: independent certification by chemical analysis and transparency to quality. Redefining the future of the healthcare supply chain, Valisure fills a major need in the market at a time when trust and openness are more important than ever.

To explore more such startups, visit Zefyron Startup Database

For more extensive analysis and Market Intelligence reports, feel free to approach us.

We try our best to fact-check and bring well-researched as well as non-plagiarized content to you. Please let us know

if there are any discrepancies in any of our published stories,

-how we can improve,

-what stories you would like us to cover

–what information you are looking for in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!

Next Article

Previous articleUSA-based Ginkgo Bioworks acquires Proof Diagnostics
Next articleSwitzerland-based Validation Cloud raises USD 5.8 million in Inaugural Funding
Jasleen Bhatia works as a content writer for VCBay News. She is pursuing her final semester in Bachelor of Business Administration from IIPS, DAVV. Driven by her keen interest in entrepreneurship and finance, she writes business-related articles.


Please enter your comment!
Please enter your name here